{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:51:32Z","timestamp":1772643092363,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ejrad.2019.108780","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T17:09:46Z","timestamp":1575997786000},"page":"108780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung"],"prefix":"10.1016","volume":"123","author":[{"given":"Kwok Sing","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chu","family":"King Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kung","family":"Boom Ting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Au Yong","family":"Ting Kun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejrad.2019.108780_bib0005","series-title":"World Cancer Report","author":"Stewart","year":"2003"},{"key":"10.1016\/j.ejrad.2019.108780_bib0010","series-title":"SEER Cancer Statistics Review","author":"Horner","year":"2006"},{"issue":"8","key":"10.1016\/j.ejrad.2019.108780_bib0015","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","volume":"31","author":"Goldstraw","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.ejrad.2019.108780_bib0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtcvs.2004.11.007","article-title":"The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival","volume":"31","author":"Cerfolio","year":"2005","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"9","key":"10.1016\/j.ejrad.2019.108780_bib0025","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00006231-200209000-00010","article-title":"Determination of the prognostic value of [18F] fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer","volume":"1","author":"Jeong","year":"2002","journal-title":"Nucl. Med. Commun."},{"issue":"1","key":"10.1016\/j.ejrad.2019.108780_bib0030","first-page":"39","article-title":"18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non\u2013small cell lung cancer","volume":"1","author":"Higashi","year":"2002","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.ejrad.2019.108780_bib0035","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.athoracsur.2004.06.102","article-title":"Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer","volume":"31","author":"Cerfolio","year":"2004","journal-title":"Ann. Thorac. Surg."},{"issue":"5","key":"10.1016\/j.ejrad.2019.108780_bib0040","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y","article-title":"The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma","volume":"1","author":"Ahuja","year":"1998","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejrad.2019.108780_bib0045","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1200\/JCO.1999.17.10.3201","article-title":"Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose\u2013positron emission tomography scan in non\u2013small-cell lung cancer: an analysis of 125 cases","volume":"17","author":"Vansteenkiste","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejrad.2019.108780_bib0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa050736","article-title":"Erlotinib in lung cancer\u2014molecular and clinical predictors of outcome","volume":"14","author":"Tsao","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5676","key":"10.1016\/j.ejrad.2019.108780_bib0055","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"4","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ejrad.2019.108780_bib0060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non\u2013small-cell lung cancer","volume":"14","author":"Shepherd","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejrad.2019.108780_bib0065","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1200\/JCO.2005.08.043","article-title":"F. Cuccurullo. EGFR mutations in non\u2013small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment","volume":"1","author":"Marchetti","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejrad.2019.108780_bib0070","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2214\/AJR.16.16532","article-title":"The value of FDG PET\/CT in treatment response assessment, follow-up, and surveillance of lung cancer","volume":"208","author":"Sheikhbahaei","year":"2017","journal-title":"AJR"},{"key":"10.1016\/j.ejrad.2019.108780_bib0075","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.2214\/AJR.17.18916","article-title":"Relation of EGFR mutation status to metabolic activity in localized lung adenocarcinoma and its influence on the use of FDG PET\/CT parameters in prognosis","volume":"1","author":"Kim","year":"2018","journal-title":"AJR"},{"issue":"5","key":"10.1016\/j.ejrad.2019.108780_bib0080","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00259-017-3885-z","article-title":"Value of 18 F\u2013FDG PET\/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients","volume":"45","author":"Lv","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"58","key":"10.1016\/j.ejrad.2019.108780_bib0085","first-page":"143","article-title":"Early predictive and prognostic value of 18F-FDG PET\/CT for response assessment in non-small cell lung cancer treated with EGFR-TKI","volume":"1","author":"Lyu","year":"2017","journal-title":"JNM"},{"issue":"1","key":"10.1016\/j.ejrad.2019.108780_bib0090","first-page":"3","article-title":"Clinical applications of 18F-FDG in oncology","volume":"30","author":"Nabi","year":"2002","journal-title":"J. Nucl. Med. Technol."},{"key":"10.1016\/j.ejrad.2019.108780_bib0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","article-title":"FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","volume":"37","author":"Boellaard","year":"2010","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.ejrad.2019.108780_bib0100","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother. Rep."},{"issue":"18","key":"10.1016\/j.ejrad.2019.108780_bib0105","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","article-title":"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non\u2013small-cell lung cancer and other solid tumors: results of a phase I trial","volume":"15","author":"Herbst","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2019.108780_bib0110","series-title":"PET And PET\/CT: a Clinical Guide","author":"Lin","year":"2009"},{"issue":"11","key":"10.1016\/j.ejrad.2019.108780_bib0115","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ejrad.2019.108780_bib0120","article-title":"Management of acquired resistance to EGFR TKI\u2013targeted therapy in advanced non-small cell lung cancer","volume":"38","author":"Wu","year":"2018","journal-title":"Mol. Cancer"},{"issue":"100","key":"10.1016\/j.ejrad.2019.108780_bib0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.lungcan.2016.07.022","article-title":"Standardized uptake value on 18F-FDG-PET\/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs","volume":"1","author":"Yoshida","year":"2016","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ejrad.2019.108780_bib0130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"31","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.ejrad.2019.108780_bib0135","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non\u2013small-cell lung cancer in Asia (IPASS)","volume":"13","author":"Fukuoka","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejrad.2019.108780_bib0140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.lungcan.2010.08.013","article-title":"Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations","volume":"31","author":"Wu","year":"2011","journal-title":"Lung Cancer."}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X19304309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X19304309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:14:16Z","timestamp":1759994056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X19304309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":28,"alternative-id":["S0720048X19304309"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2019.108780","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2019.108780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108780"}}